UBS AM
TVRD

UBS AM’s Tvardi Therapeutics TVRD Stock Holding History

UBS AM’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,344
Closed -$414K – 2699
2023
Q2 		$414K Hold
2,344
– – ﹤0.01% 2378
2023
Q1 		$414K Hold
2,344
– – ﹤0.01% 2378
2022
Q4 		$906K Buy
2,344
+14
+0.6% +$5.32K ﹤0.01% 1891
2022
Q3 		$785K Buy
2,330
+777
+50% +$281K ﹤0.01% 2109
2022
Q2 		$511K Hold
1,553
– – ﹤0.01% 2305
2022
Q1 		$679K Hold
1,553
– – ﹤0.01% 2336
2021
Q4 		$681K Hold
1,553
– – ﹤0.01% 2411
2021
Q3 		$864K Sell
1,553
-134
-8% -$67.2K ﹤0.01% 2246
2021
Q2 		$867K Buy
1,687
+4
+0.2% +$2.54K ﹤0.01% 2284
2021
Q1 		$1.32M Buy
1,683
+28
+2% +$19.2K ﹤0.01% 1951
2020
Q4 		$901K Hold
1,655
– – ﹤0.01% 2043
2020
Q3 		$758K Buy
1,655
+685
+71% +$398K ﹤0.01% 1953
2020
Q2 		$597K Buy
970
+89
+10% +$49.2K ﹤0.01% 2041
2020
Q1 		$419K Sell
881
-57
-6% -$31K ﹤0.01% 2039
2019
Q4 		$544K Buy
938
+48
+5% +$33.7K ﹤0.01% 2199
2019
Q3 		$586K Buy
890
+427
+92% +$355K ﹤0.01% 2206
2019
Q2 		$358K Sell
463
-331
-42% -$233K ﹤0.01% 2346
2019
Q1 		$561K Buy
794
+436
+122% +$261K ﹤0.01% 2066
2018
Q4 		$168K Sell
358
-228
-39% -$147K ﹤0.01% 2441
2018
Q3 		$505K Hold
586
– – ﹤0.01% 2082
2018
Q2 		$404K Buy
+586
New +$298K ﹤0.01% 2189
2017
Q4 		– Sell
-3,962
Closed -$1.95M – 2606
2017
Q3 		$1.95M Hold
3,962
– – ﹤0.01% 1416
2017
Q2 		$2.19M Sell
3,962
-3,969
-50% -$2.52M ﹤0.01% 1329
2017
Q1 		$5.25M Buy
+7,931
New +$4.24M 0.01% 1008
2016
Q2 		– Sell
-300
Closed -$67K – 2641
2016
Q1 		$67K Hold
300
– – ﹤0.01% 2602
2015
Q4 		$182K Buy
+300
New +$165K ﹤0.01% 2559

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

UBS AM's TVRD Position: Q3 2023 in Review

UBS AM sold out of Tvardi Therapeutics (TVRD) in Q3 2023, closing a stake of 2,344 shares — an estimated $414K sold.

UBS AM first reported a position in TVRD in Q4 2015 and held it in 26 quarters. The position peaked at $5.25M in Q1 2017. 122 funds tracked by Wall St. Rank hold TVRD as of Q3 2023.

  • UBS AM reported no remaining Tvardi Therapeutics position as of Q3 2023 after selling out during the quarter.
  • UBS AM sold 2,344 Tvardi Therapeutics shares in Q3 2023, an estimated $414K.
  • UBS AM first reported a position in Tvardi Therapeutics in Q4 2015 and held it in 26 quarters.
  • UBS AM's Tvardi Therapeutics position peaked at $5.25M in Q1 2017.
  • 122 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.